Indication

CCR5

1 clinical trial

2 products

Clinical trial

A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

Status: Withdrawn, Estimated PCD: 2023-05-27

Product

Product